IBT B — Infant Bacterial Therapeutics AB Income Statement
0.000.00%
Last trade - 00:00
- SEK1.23bn
- SEK899.53m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 47.2 | 71.9 | 44.6 | 65.8 | 135 |
Operating Profit | -47.2 | -71.9 | -44.6 | -65.8 | -135 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -46.3 | -72 | -45 | -65.5 | -123 |
Net Income After Taxes | -46.3 | -72 | -45 | -65.5 | -123 |
Net Income Before Extraordinary Items | |||||
Net Income | -46.3 | -72 | -45 | -65.5 | -123 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -46.3 | -72 | -45 | -65.5 | -123 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4.13 | -6.41 | -4.01 | -5.83 | -9.95 |
Dividends per Share |